2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2021
Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics.
Mackow NA, Abi-Raad R, Kerantzas CA, Hui P, Malinis M, Azar MM. Increased Detection of Mycobacterium tuberculosis Disease Using a Tissue-Based Laboratory-Developed Polymerase Chain Reaction Assay Compared to Standard Diagnostics. American Journal Of Tropical Medicine And Hygiene 2021, 105: 1657-1661. PMID: 34544041, PMCID: PMC8641361, DOI: 10.4269/ajtmh.21-0104.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCulture TechniquesFemaleHumansLungLymph NodesMaleMiddle AgedMycobacterium tuberculosisPleuraReal-Time Polymerase Chain ReactionReference StandardsRetrospective StudiesSensitivity and SpecificitySputumTuberculosisTuberculosis, Lymph NodeTuberculosis, Multidrug-ResistantTuberculosis, PleuralTuberculosis, PulmonaryConceptsComposite reference standardMTB PCRAFB cultureMycobacterium tuberculosisPolymerase chain reactionAcid-fast bacilli smearMycobacterium tuberculosis diseasePositive AFB cultureChain reactionReal-time polymerase chain reactionStandard diagnosticsBacilli smearMTB casesTuberculosis diseaseClinical sensitivityLong turnaround timeXpertClinical performanceReference standardPCRVariable sensitivityTurnaround timeLymphPatientsTuberculosisDHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBenzodiazepinesBystander EffectCell Line, TumorCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunoconjugatesMiddle AgedPrimary Cell CultureReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsHER2/neuPrimary USC cell linesUSC cell linesUterine serous carcinomaSerous carcinomaHER2/Cell linesBystander killingHER2/neu protein expressionHER2/neu overexpressionProtein expressionNovel treatment optionsAggressive histologic variantNeu protein expressionHER2 protein expressionC-erbB2 gene amplificationSignificant bystander killingUSC xenograftsEndometrial cancerNegative tumorsPoor prognosisPositive tumorsTreatment optionsPreclinical activityHistologic variants
2020
Genital tuberculosis screening at an academic fertility center in the United States
Tal R, Lawal T, Granger E, Simoni M, Hui P, Buza N, Pal L. Genital tuberculosis screening at an academic fertility center in the United States. American Journal Of Obstetrics And Gynecology 2020, 223: 737.e1-737.e10. PMID: 32497612, DOI: 10.1016/j.ajog.2020.05.045.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, HabitualAcademic Medical CentersAdultEndometritisEndometriumFemaleFertility ClinicsGynatresiaHumansIncidenceInfertility, FemaleInterferon-gamma Release TestsLatent TuberculosisMass ScreeningMycobacterium tuberculosisPolymerase Chain ReactionProspective StudiesTuberculosis, Female GenitalUnited StatesYoung AdultConceptsFemale genital tuberculosisQuantiFERON-TB GoldGenital tuberculosisAcademic fertility centerLatent tuberculosisChest X-rayPositive test resultsFertility centerPolymerase chain reactionEndometrial biopsyMycobacterium tuberculosisChain reactionQuantiFERON-TB Gold resultsProspective cohort studyRecurrent pregnancy lossReproductive technology treatmentAcid-fast bacilliMultiple diagnostic modalitiesNegative test resultsGranulomatous endometritisNeonatal complicationsEndometrial samplingNeonatal morbidityCohort studyAsherman's syndromeHeterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease
Zheng XZ, Qin XY, Chen SW, Wang P, Zhan Y, Zhong PP, Buza N, Jin YL, Wu BQ, Hui P. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. Modern Pathology 2020, 33: 1979-1988. PMID: 32404958, DOI: 10.1038/s41379-020-0566-4.Peer-Reviewed Original ResearchConceptsNon-molar gestationsGestational trophoblastic diseaseTrophoblastic diseaseHigh riskGestational trophoblastic neoplasiaProducts of conceptionPatient demographicsClinical followClinical outcomesGynecology HospitalTrophoblastic neoplasiaBeijing ObstetricsFIGO criteriaChinese patientsClinical prognosisPatient managementLarge cohortGestationMolar gestationDiseaseGenetic abnormalitiesChromosomal monosomyChromosomal aneuploidyHydatidiformUniparental disomyExtragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell Origin
Simpson S, Simoni M, Hui P, Taylor H, Buza N. Extragonadal Yolk Sac Tumor Limited to the Myometrium: Report of a Case With Potential Fertility Preservation and Molecular Analysis Suggesting Germ Cell Origin. International Journal Of Gynecological Pathology 2020, 39: 247-253. PMID: 31033797, DOI: 10.1097/pgp.0000000000000601.Peer-Reviewed Original ResearchConceptsYolk sac tumorExtragonadal yolk sac tumorGerm cell originFuture fertilityIntraoperative frozen section evaluationCell originPatient's strong desirePostpubertal female patientsEvidence of diseaseFrozen section evaluationMarked nuclear atypiaClear treatment algorithmRare malignant neoplasmHigh-grade malignancyEosinophilic hyaline globulesNext-generation sequencing resultsAdjuvant chemotherapySurgical stagingAbdominal myomectomyNulligravid womenIrregular bleedingUterine closureWedge resectionYounger patientsFemale patientsMolecular and clinicopathologic characterization of intravenous leiomyomatosis
Ordulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Molecular and clinicopathologic characterization of intravenous leiomyomatosis. Modern Pathology 2020, 33: 1844-1860. PMID: 32341498, PMCID: PMC7483566, DOI: 10.1038/s41379-020-0546-8.Peer-Reviewed Original ResearchConceptsIntravenous leiomyomatosisAggressive clinical behaviorClinical behaviorArray comparative genomic hybridizationCyclin D1Uterine smooth muscle tumorsSmooth muscle tumorsSmooth muscle proliferationRecurrent chromosome alterationsCommon genetic alterationsFH immunohistochemistryClinicopathologic characterizationImmunohistochemical findingsMesenchymal tumorsMuscle tumorsBenign appearanceMuscle proliferationUterine leiomyomaGroup 1Group 3Nonneoplastic tissuesIndex scoreVascular morphologyProtein expressionComparative genomic hybridizationFrequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients
Wong S, Hui P, Buza N. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients. Modern Pathology 2020, 33: 1172-1181. PMID: 31932681, DOI: 10.1038/s41379-020-0455-x.Peer-Reviewed Original ResearchConceptsLynch syndrome patientsLynch syndromeMMR protein expressionSporadic endometrial carcinomasSyndrome patientsEndometrial cancerEndometrial glandsEndometrial carcinomaProtein expressionLynch syndrome-associated endometrial cancerGermline mutationsMismatch repair protein expressionMMR protein immunohistochemistryEndometrial cancer patientsNonneoplastic endometriumBenign endometrial tissuesMicrosatellite instability testingMMR protein lossGermline mutation analysisDNA mismatch repair genesRepair protein expressionMismatch repair genesBackground endometriumMMR immunohistochemistryProphylactic hysterectomy
2019
Inverted duplication, triplication and quintuplication through sequential breakage‐fusion‐bridge events induced by a terminal deletion at 5p in a case of spontaneous abortion
Chai H, Grommisch B, DiAdamo A, Wen J, Hui P, Li P. Inverted duplication, triplication and quintuplication through sequential breakage‐fusion‐bridge events induced by a terminal deletion at 5p in a case of spontaneous abortion. Molecular Genetics & Genomic Medicine 2019, 7: e00965. PMID: 31478360, PMCID: PMC6785443, DOI: 10.1002/mgg3.965.Peer-Reviewed Original ResearchPrognostic markers for immunodeficiency-associated primary central nervous system lymphoma
Kaulen LD, Galluzzo D, Hui P, Barbiero F, Karschnia P, Huttner A, Fulbright R, Baehring JM. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. Journal Of Neuro-Oncology 2019, 144: 107-115. PMID: 31190317, DOI: 10.1007/s11060-019-03208-w.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaDiffusion-weighted imaging patternsMagnetic resonance imagingCentral nervous system lymphomaNervous system lymphomaSystem lymphomaPeripheral enhancementDWI patternsPCNSL casesImaging featuresPrognostic markerHuman immunodeficiency virus (HIV) infectionKaplan-Meier survival analysisDiffuse large B-cell lymphomaYale-New Haven HospitalLarge B-cell lymphomaMedian overall survivalImmunodeficiency virus infectionPredictors of survivalSolid organ transplantationImmunoglobulin heavy chain gene rearrangementPeripheral contrast enhancementLog-rank testMajor risk factorHeavy chain gene rearrangementAdjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.Peer-Reviewed Original ResearchConceptsLow-grade endometrial stromal sarcomaRecurrence-free survivalStage I patientsEndometrial stromal sarcomaAromatase inhibitorsI patientsStage IIStromal sarcomaAdvanced low-grade endometrial stromal sarcomaMean recurrence-free survivalLonger recurrence-free survivalAdjuvant hormonal therapyMedian followProgestin groupUnderwent hysterectomyHormonal therapyDisease recurrenceSide effectsPatientsStage IProgestinsMonthsSarcomaDiseaseTreatmentPrecision genotyping diagnosis of lung tumors with trophoblastic morphology in young women
Buza N, Baine I, Hui P. Precision genotyping diagnosis of lung tumors with trophoblastic morphology in young women. Modern Pathology 2019, 32: 1271-1280. PMID: 31028360, DOI: 10.1038/s41379-019-0275-z.Peer-Reviewed Original ResearchConceptsGestational choriocarcinomaLung carcinomaLung massClinical historyLung tumorsGestational originSerum beta-hCG levelsYoung womenTrophoblastic differentiationMetastatic gestational choriocarcinomaSerum beta-hCGBeta-hCG levelsEvidence of diseaseUnique diagnostic challengePrimary lung carcinomaGestational trophoblastic neoplasiaDifferent chemotherapeutic regimensDifferent primary sitesWedge resectionBeta-hCGFemale patientsMetastatic choriocarcinomaThird patientChemotherapeutic regimensImmunophenotypical featuresPaternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles
Buza N, McGregor SM, Barroilhet L, Zheng X, Hui P. Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. Modern Pathology 2019, 32: 1180-1188. PMID: 30952972, DOI: 10.1038/s41379-019-0266-0.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, MissedAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChromosomes, Human, Pair 11CyclophosphamideDactinomycinEtoposideFemaleGenetic LociGenetic Predisposition to DiseaseHumansHydatidiform MoleMaleMethotrexatePhenotypePregnancyTreatment OutcomeTyrosine 3-MonooxygenaseUniparental DisomyUterine NeoplasmsVincristineConceptsPaternal uniparental isodisomyAbnormal trophoblastic proliferationCases of gestationUneventful clinical courseAggressive clinical behaviorUniparental isodisomyTyrosine hydroxylase locusMultiagent chemotherapyClinical courseFirst trimesterClinical complicationsImmunohistochemical featuresClinical behaviorMissed abortionAbnormal gestationsTyrosine hydroxylasePatientsTrophoblastic proliferationVillous cytotrophoblastsStromal cellsPhenotypical presentationChorionic villiGenetic conditionsP57 expressionGestationTen-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.Peer-Reviewed Original ResearchConceptsType 2 cancerHormone replacement therapyCox regression modelType 2 diseaseRisk factorsEndometrial cancerType 1Use of HRTLess obese patientsBaseline risk factorsEndometrial cancer casesMajor cardiovascular diseasesObese patientsOral contraceptivesOverall survivalClinical courseDiabetes mellitusRetrospective reviewRegression modelsReplacement therapyCardiovascular diseaseCancer casesAdvanced stageHigh mortalityRecurrence
2018
Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions
Liu Y, Blakely M, Sigel K, Thin TH, Hui P, Donovan M, Gaisa MM. Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions. AIDS 2018, 32: 2309-2316. PMID: 30005024, PMCID: PMC6862769, DOI: 10.1097/qad.0000000000001957.Peer-Reviewed Original ResearchConceptsLow-grade squamous intraepithelial lesionsAnal low-grade squamous intraepithelial lesionsSquamous intraepithelial lesionsHigh-grade squamous intraepithelial lesionsBiomarker p16Intraepithelial lesionsIndex lesionP16 immunohistochemistryProgression riskHigh-risk human papillomavirus DNACD4 T-cell countFormer smoker statusHistory of condylomaT-cell countsHR-HPV DNAYear of diagnosisHuman papillomavirus DNASemi-quantitative scoring systemAssociation of predictorsLogistic regression modelsOnly significant predictorOrdinal logistic regression modelsClinical outcomesUnderwent surveillanceRetrospective studyInhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clinical Cancer Research 2018, 24: 4845-4853. PMID: 29941483, PMCID: PMC6168417, DOI: 10.1158/1078-0432.ccr-18-0864.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsAntineoplastic AgentsApoptosisAurora Kinase AAurora Kinase BAzepinesCell Line, TumorCell ProliferationCystadenocarcinoma, SerousDose-Response Relationship, DrugEndometrial NeoplasmsExome SequencingFemaleGene Expression Regulation, NeoplasticHumansMiceMiddle AgedPhosphorylationPrimary Cell CultureProteinsProto-Oncogene Proteins c-mycTriazolesUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaPrimary USC cell linesUSC cell linesC-myc expressionCell linesC-MycChemotherapy-resistant diseaseQRT-PCRHigh c-myc expressionDose-dependent decreaseDose-dependent increasePotential therapeutic targetEffective therapeutic agentMouse xenograft modelClin Cancer ResFresh frozen tumor tissueC-myc gene amplificationUSC xenograftsEndometrial cancerAggressive variantSerous carcinomaWhole-exome sequencing studiesClinical studiesConcentrations/dosesXenograft modelFOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors
Buza N, Wong S, Hui P. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors. International Journal Of Gynecological Pathology 2018, 37: 305-315. PMID: 28700438, DOI: 10.1097/pgp.0000000000000426.Peer-Reviewed Original ResearchConceptsSex cord-stromal tumorsAdult granulosa cell tumorGranulosa cell tumorsOvarian sex cord-stromal tumorsCell tumorsReticulin patternFOXL2 mutationStaining patternSertoli-Leydig cell tumorFOXL2 mutation statusAbundant pale cytoplasmSingle institutional cohortThird of casesWild-type tumorsFOXL2 mutation analysisNegative tumorsPositive tumorsTumor sizeReticulin stainingType tumorsPale cytoplasmNuclear atypiaMutation statusPositive casesTumorsMicroRNA signatures discriminate between uterine and ovarian serous carcinomas
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaDiagnosis, DifferentialFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansMicroRNAsMiddle AgedNeoplasm GradingNeoplasms, Cystic, Mucinous, and SerousOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPhenotypePredictive Value of TestsReproducibility of ResultsRetrospective StudiesTranscriptomeUterine NeoplasmsConceptsHigh-grade serous carcinomaOvarian serous carcinomaSerous carcinomaOvarian malignancyPrimary ovarian high-grade serous carcinomaOvarian high-grade serous carcinomaMiRNA signatureEndometrial serous carcinomaHigh-grade ovarian serous carcinomaUterine serous carcinomaEndometrial counterpartOvarian primaryTaqMan Low Density Array technologySynchronous primariesEndometrial cancerMetastatic tumorsCarcinomaPrimary siteSignature panelPathological determinationMicroRNA signatureSignificant discriminatory powerCancer cellsMalignancyLineage characteristics
2017
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome
Zuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Modern Pathology 2017, 31: 350-357. PMID: 29027536, DOI: 10.1038/modpathol.2017.121.Peer-Reviewed Original ResearchConceptsAtypical proliferative serous tumorNon-invasive implantsDisease-specific survivalSerous borderline tumorsHigh recurrence rateWorse disease-specific survivalStage IIIC diseaseKRAS mutationsInvasive implantsBRAF V600E mutationBorderline tumorsSerous tumorsRecurrence rateIIIC diseaseClinical outcomesHistological subtypesPrognostic indicatorExtraovarian implantsV600E mutationLow-grade serous carcinomaUnfavorable disease-specific survivalAdverse clinical outcomesHigher stage diseaseSignificant prognostic indicatorBRAF mutation frequencySuperior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecologic Oncology 2017, 147: 145-152. PMID: 28705408, PMCID: PMC5605415, DOI: 10.1016/j.ygyno.2017.07.009.Peer-Reviewed Original ResearchConceptsHigh HER2/neu expressionHER2/neu expressionEpithelial ovarian cancerHER2/neuAnti-tumor activityEOC cell linesT-DM1Neu expressionChemotherapy-resistant epithelial ovarian cancerLimited anti-tumor activityAntibody-dependent cell-mediated cytotoxicity (ADCC) activityCell linesSuperior anti-tumor activityCombination of trastuzumabLethal gynecologic malignancyEpithelial ovarian carcinomaTumor growth inhibitionEOC xenograftsGynecologic malignanciesPreclinical dataOvarian carcinomaOvarian cancerClinical studiesXenograft modelSingle agent